RE:RE:RE:RE:RE:RE:RE:RE:RE:CG Oncologyor more precisely, successfully using an approved fda surrogate enpoint, obtaining the marketing authorization which comes with a fast track approval, and then conducting a phase 4 post-marketing study to provide the fda with additional information including the treatment or drug's risks, benefits, and best use utilizing a medium to large size trial which in not randomized as opposed to conducting a phase 3 thrial consisting of hundreds or thousands of people in a trial which is usually randomized.
seems like oncy's current approach is electing to take the shortest distance between two points.